Nigel Russell, MD, from Nottingham University Hospitals NHS Trust, Nottingham, UK talks about new and emerging drug targets in acute myeloid leukemia (AML). Prof Russell discusses the FLT3 mutation, which is one of the most established targets and has been a focus of research for several years, acute promyelocytic leukemia (APL), as well as the IDH1, IDH2 and NPM1 mutations.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.